美金刚治疗成人注意力缺陷多动障碍的执行功能缺陷
Memantine in the Treatment of Executive Function Deficits in Adults With ADHD.
作者信息
Biederman Joseph, Fried Ronna, Tarko Laura, Surman Craig, Spencer Thomas, Pope Amanda, Grossman Rebecca, McDermott Katie, Woodworth K Yvonne, Faraone Stephen V
机构信息
1 Massachusetts General Hospital, Boston, MA, USA.
2 State University of New York Upstate Medical University, Syracuse, MA, USA.
出版信息
J Atten Disord. 2017 Feb;21(4):343-352. doi: 10.1177/1087054714538656. Epub 2016 Jul 28.
OBJECTIVE
To evaluate the efficacy and safety of memantine hydrochloride as an adjunct to stimulant pharmacotherapy for treating executive function deficits (EFDs) in adults with ADHD.
METHOD
This was a 12-week, double-blind, placebo-controlled, randomized clinical trial of memantine added to open-label treatment with stimulant medication. Because of the small sample size, we considered a standardized mean difference (equivalent to effect size) of ≥0.5 and odds ratios ≥2 as indicators of trend improvements.
RESULTS
Twelve participants received memantine and 14 received a placebo. Trend improvements favoring memantine were observed on Behavior Rating Inventory of Executive Functions-Adult Inhibition and Self-Monitor subscales when compared with Placebo. No significant changes were noted on the Cambridge Neuropsychological Test Automated Battery.
CONCLUSION
Among adults with ADHD and EFDs, adjunct treatment with memantine to osmotic release oral system-methylphenidate (OROS-MPH) was associated with improvements in selective areas of executive functioning, supporting the need for further research.
目的
评估盐酸美金刚作为兴奋剂药物治疗成人注意力缺陷多动障碍（ADHD）执行功能缺陷（EFD）辅助用药的疗效和安全性。
方法
这是一项为期12周的双盲、安慰剂对照、随机临床试验，将美金刚添加到开放标签的兴奋剂药物治疗中。由于样本量较小，我们将标准化均数差（相当于效应量）≥0.5和比值比≥2作为趋势改善的指标。
结果
12名参与者接受了美金刚治疗，14名接受了安慰剂治疗。与安慰剂相比，在执行功能行为评定量表-成人抑制和自我监控子量表上观察到有利于美金刚的趋势改善。剑桥神经心理测试自动成套系统未发现显著变化。
结论
在患有ADHD和EFD的成人中，美金刚作为渗透型缓释口服系统-哌甲酯（OROS-MPH）的辅助治疗与执行功能的某些特定领域的改善相关，支持进一步研究的必要性。
Zotero 插件